|
注册号: Registration number: |
ChiCTR2300070633 |
|
最近更新日期: Date of Last Refreshed on: |
2023-08-18 20:57:58 |
|
注册时间: Date of Registration: |
2023-04-19 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
中度到重度慢性阻塞性肺疾病患者规范化呼吸康复项目:一项基于厦门健康医疗大数据的多中心、随机对照、前瞻性研究 |
|
Public title: |
Standardized respiratory rehabilitation program for patients with moderate to severe chronic obstructive pulmonary disease: A multicenter, randomized controlled and prospective study based on Xiamen healthcare big data |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
中度到重度慢性阻塞性肺疾病患者规范化呼吸康复项目:一项基于厦门健康医疗大数据的多中心、随机对照、前瞻性研究 |
|
Scientific title: |
Standardized respiratory rehabilitation program for patients with moderate to severe chronic obstructive pulmonary disease: A multicenter, randomized controlled and prospective study based on Xiamen healthcare big data |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
鄢锟 |
研究负责人: |
陈玲玲,钟南山,郑劲平,姜燕 |
|
Applicant: |
Kun Yan |
Study leader: |
Lingling Chen, Nanshan Zhong, Jingpin Zheng, Yan Jiang |
|
申请注册联系人电话: Applicant telephone: |
+86 13859984190 |
研究负责人电话:
Study leader's |
+86 13860115565 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
630519522@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
13806045384@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
福建省厦门市海沧区海裕路89号 |
研究负责人通讯地址: |
福建省厦门市海沧区海裕路89号 |
|
Applicant address: |
89 Haiyu Road, Haicang District, Xiamen, Fujian |
Study leader's address: |
89 Haiyu Road, Haicang District, Xiamen, Fujian |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
厦门市海沧医院 |
||
|
Applicant's institution: |
Xiamen Haicang Hospital |
||
|
研究负责人所在单位: |
厦门市海沧医院 |
||
|
Affiliation of the Leader: |
Xiamen Haicang Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
SY-2022002 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
厦门市海沧医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Xiamen Haicang Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-12-12 00:00:00 | ||
|
伦理委员会联系人: |
苏晶晶 |
||
|
Contact Name of the ethic committee: |
Jingjing Su |
||
|
伦理委员会联系地址: |
福建省厦门市海沧区海裕路89号 |
||
|
Contact Address of the ethic committee: |
89 Haiyu Road, Haicang District, Xiamen, Fujian |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 592 65899600 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
厦门市海沧医院 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor: |
Xiamen Haicang Hospital |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
福建省厦门市海沧区海裕路89号 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor's address: |
89 Haiyu Road, Haicang District, Xiamen, Fujian |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
经费或物资来源: |
厦门市卫生健康委员会 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Source(s) of funding: |
Xiamen Municipal Health Commission |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病: |
慢性阻塞性肺疾病 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Target disease: |
Chronic obstructive pulmonary disease |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究目的: |
主要目的:对中度到重度慢性阻塞性肺疾病患者开展规范化居家呼吸康复训练,并评估肺康复锻炼对急性加重频率(次数/人/年)及呼吸肌力量的改善情况。次要目的:探索中度到重度慢性阻塞性肺疾病患者慢病管理现状,总结频繁急性加重人群的临床特征;探索通过物联网设备进行急性加重预警监测的可行性及有效性;开展稳定期/急性加重期慢性阻塞性肺疾病全球倡议组织(Global Initiative for Chronic Obstructive Lung Disease,GOLD2021)指南推荐用药方案一致性评价。 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Objectives of Study: |
Main objective: To evaluate the effect of home-based respiratory rehabilitation on the frequency of exacerbations (times/person/year) and respiratory muscle strength in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Secondary objectives: To explore the current status of chronic disease management in patients with moderate to severe chronic obstructive pulmonary disease (COPD) and summarize the clinical characteristics of frequent acute exacerbations. To explore the feasibility and effectiveness of early warning and monitoring of acute exacerbations through Internet of things devices. To evaluate the consistency of medication regimens recommended by the Global Initiative for Chronic Obstructive Lung Disease (GOLD2021) guidelines in stable/acute exacerbation. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
排除标准: |
1. 筛选期排除标准: (1)合并慢阻肺以外的重要疾病; 重要疾病定义为:研究者认为合并某一种疾病或疾病的严重程度可能导致患者因参与研究而使其处于危险之中,或可能影响研究结果,或明显影响了患者参与研究的能力;近3个月患心肌梗死、脑卒中、休克。 (2)实验室检查(如血常规、血生化、尿常规)有显著临床意义异常的患者,如果有异常则定义为排除标准(1)中的重要疾病; (3)合并有临床意义的尘肺等限制性通气功能障碍疾病; (4)合并未治愈或进展期的恶性肿瘤; (5)合并有哮喘; (6)合并活动性肺结核; (7)合并有危及生命的肺栓塞,合并有临床意义的α1-抗胰蛋白酶缺乏症或囊性纤维化的患者; (8)有肺叶切除术史; (9)下肢活动障碍,无法独自完成六分钟步行试验评估; (10)符合肺功能检查绝对禁忌症; (11)筛选前3个月内参加过其他呼吸系统临床试验; (12)研究者认为不适于参加临床研究的患者,如未控制的高血压病(收缩压>180mmHg、舒张压>110mmHg)、未控制的高血糖状态等。 2. 随访期排除标准: 筛选期内或入组后,符合下述任一项条件的受试者不可进入随访期*: (1)并发其它急性疾病需要用干预且影响本研究; (2)未按要求完成所需检查项目,并导致不能进行主要指标评价; (3)随访期间出现经研究者判断需要退出试验的严重不良事件; (4)随访期间受试者妊娠; (5)随访期间自行退出、失访或死亡; (6)发现受试者不符合任一项纳入标准,或符合任一项排除标准。 符合以上任一项排除条件的受试者应排除纳入随访期。 *已知或发现受试者对智能手表的本体和/或表带存在不可耐受的过敏性接触皮炎,则退出智能手表亚组并回收智能手表。 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Exclusion criteria: |
1. Exclusion criteria during the screening period: (1) Complicated with important diseases other than COPD; A significant disease was defined as one that the investigator considered to be associated with a disease or severity of the disease that might put the patient at risk for participating in the study, might affect the study results, or significantly affect the patient's ability to participate in the study. He suffered from myocardial infarction, stroke, and shock in the past 3 months; (2) Patients with clinically significant abnormalities in laboratory tests (such as blood routine, blood biochemistry, and urine routine) were defined as important diseases in the exclusion criteria (1); (3) Complicated with clinically significant pneumoconiosis and other restrictive ventilation dysfunction diseases; (4) Combined with uncured or advanced malignant tumors; (5) Combined with asthma; (6) Complicated with active pulmonary tuberculosis; (7) Patients with life-threatening pulmonary embolism, clinically significant α1-antitrypsin deficiency or cystic fibrosis; (8) History of lobectomy; (9) Inability to complete the 6-minute walk test alone; (10) Meet the absolute contraindication of pulmonary function test; (11) Participated in other respiratory clinical trials within 3 months before screening; (12) Patients with uncontrolled hypertension (systolic blood pressure >180mmHg, diastolic blood pressure >110mmHg) or uncontrolled hyperglycemia considered by the investigator to be unsuitable for clinical study. 2. Exclusion criteria during the follow-up period: During the screening period or after enrollment, participants who met any of the following criteria were not eligible for the follow-up period * : (1) Concurrent acute diseases requiring intervention and affecting the study; (2) The required inspection items were not completed according to the requirements, which resulted in the inability to evaluate the main indicators; (3) Serious adverse events requiring withdrawal from the trial according to the investigator's judgment during the follow-up period; (4) Pregnancy during follow-up; (5) Withdrawal, loss of follow-up, or death during follow-up; (6) If the subjects did not meet any of the inclusion criteria or met any of the exclusion criteria. Subjects who met any of the above exclusion criteria were excluded from inclusion in the follow-up period. * If a subject is known or found to have intolerable allergic contact dermatitis with the body and/or band of the smartwatch, exit the smartwatch subgroup and recycle the smartwatch. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-01-01 00:00:00至 To 2025-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-04-19 00:00:00 至 To 2023-10-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
研究使用区段随机化方法,依托厦门i健康平台实现随机化分组。区段随机化根据受试者进入临床试验的时序分为多个区段,再对每个区段随机化分组。按肺康复锻炼组与随访对照组的比例(2:1),固定区组大小为6,区组编码方法共有15种,分别对应数字1–15。基于15种区组编码方法构建基础编码字典,采用Java编写随机函数模块,为每区段随机生成1–15个数字中的一个,映射到相应区组编码字典,通过厦门i健康平台实现入组受试者的随机分组,重复此过程直至收集到预先规定的受试者数。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The study used a segmented randomization method and relied on the Xiamen i Health platform to achieve randomization. Block randomization was performed in blocks according to the timing of trial entry, with randomization in each block. According to the ratio of pulmonary rehabilitation exercise group to follow-up |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无。 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Not to share |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
每位研究者将获得独立的用户名和密码,研究中心指定经培训的人员在规定的时间内通过安全网络将原始数据录入eCRF中,系统将自动检查eCRF中的数据,如有异常会产生相应的警告或质疑信息。在数据库锁定之前,研究者将使用电子签名确认数据,以保证数据记录的准确性。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Each investigator will be given an independent user name and password, and the study site will assign trained personnel to enter raw data into eCRF through a secure network within a specified time. The system will automatically check the data in eCRF, and if there is any abnormality, the corresponding warning or challenge message will be generated. Prior to database lock, investigators will confirm the data with electronic signatures to ensure the accuracy of data recording. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |